Axitinib: VEGFR/PDGFR tyrosine kinase inhibitor antiangiogenic agent

Drugs of the Future

Volumn 32, Issue 5, 2007, Pages 389-398

  Revill, P ^a   Mealy, N ^a   Bayes M ^a   Bozzo, J ^a   Serradell, N ^a   Rosa, E ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AG 13736; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; CP 868596; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; N METHYL 2 [3 [2 (2 PYRIDYL)VINYL] 1H INDAZOL 6 YLSULFANYL]BENZAMIDE; PLACEBO; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEWIS CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEINURIA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; VOMITING; WEIGHT REDUCTION;

EID: 34547784621     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.05.1102211     Document Type: Article

References (57)

1. Kania, R.S., Wallace, M.B., Borchardt, A.J. et al. (Agouron Pharmaceuticals, Inc.). Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. EP 1614683, JP 2003503481, JP 2006348043, WO 0102369.
2. Babu, S., Dagnino, R. Jr., Ouellette, M.A., Shi, B., Tian, Q., Zook, S.E. (Pfizer, Inc.). Methods for preparing indazole compounds. WO 2006048745.
3. Ewanicki, B.L., Flahive, E.J., Kasparian, A.J. et al. (Pfizer, Inc.; Agouron Pharmaceuticals, Inc.). Methods of preparing indazole compounds. US 2006094881, WO 2006048744.
4. Weidner, N., Semple, J.P., Welch, W.R. et al. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991, 324(12): 1-8.
5. Hanahan, D., Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3): 353-64.
6. Salven, P., Manpaa, H., Orpana, A., Alitalo, K., Joensuu, H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997, 3(5): 647-51.
7. Fontanini, G., Boldrini, L., Chine, S. et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 1999, 79(2): 363-9.
8. Mattern, J., Koomagi, R., Volm, M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73(7): 931-4.
9. Sorbera, L.A., Leeson, P.A., Bayes, M. Bevacizumab. Drugs Fut 2002, 27(7): 625-32.
10. Neufeld, G., Cohen, T., Gengrinovitch, S., Poitorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13(1): 9-22.
11. Gille, H., Kowalski, J., Li, B. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001, 276(5): 3222-30.
12. Hicklin, D.J., Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5): 1011-27.
13. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9: 669-76.
14. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004, 25: 581-611.
15. Lee, D., Heymach, J.V. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 2006, 7(5): 304-8.
16. Kamba, T., Tam, B.Y., Hashizume, H. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006, 290(2): H560-76.
17. Hu-Lowe, D., Hallin, M., Feeley, R. et al. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 5356.
18. Wickman, G., Hallin, M., Amundson, K. et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. 94th Annu Meet Am Assoc Cancer Res (AACR) (July 10-14, Washington, D.C.) 2003, Abst 3780.
19. Hu-Lowe, D., Heller, D., Brekken, J. et al. Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGF receptor tyrosine kinases. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 5357.
20. Inai, T., Mancuso, M., Hashizume, H. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165(1): 35-52.
21. Nakahara, T., Norberg, S.M., Shalinsky, D.R., Hu-Lowe, D.D., McDonald, D.M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006, 66(3): 1434-45.
22. Yao, V.J., Ozawa, M.G., Varner, A.S. et al. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res 2006, 66(5): 2639-49.
23. Mancuso, M.R., Davis, R., Norberg, S.M. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116(10): 2610-21.
24. Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C.J., Hu-Lowe, D., McDonald, D.M. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006, 290(2): H547-59.
25. Hu-Lowe, D., Grazzini, M.L., Amundson, K. et al. Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors. Eur J Cancer-Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 71.
26. Hu-Lowe, D.D., Grazzini, M.L. Significant enhancement of anti-tumor efficacy of VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in combination with docetaxel in chemorefractory and/or orthotopic xenograft tumor models in mice. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 2032.
27. Fenton, B.M., Paoni, S.F. Combined effects of VEGF/PDGF receptor tyrosine kinase inhibitors plus fractionated radiation on DU145 prostate carcinoma vasculature and oxygenation. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 973.
28. Paul, S., Foutz, T.J., Calleri, A., Gobbi, A., Hu-Lowe, D., Shalinsky, D.R. AG-013736, a potent VEGF/PDGF receptor tyrosine kinase inhibitor, is active against lymphoma growth and chemotherapy-induced vasculogenesis. Blood 2003, 102(11, Part 1): Abst 2397.
29. Wilmes, L.J., Pallavicini, M.G., Fleming, L.M. et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007, 25(3): 319-27.
30. Wilmes, L.J., Hylton, N.M., Wang, D. et al. AG-013736, a novel VEGFR TK inhibitor, suppresses tumor growth and vascular permeability in human BT474 breast cancer xenografts in nude mice. Proc Am Assoc Cancer Res (AACR) 2003, 44: Abst 3772.
31. Li, K.L., Wilmes, L.J., Henry, R.G. et al. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 2005, 22(4): 511-9.
32. Herbst, R.S., Rugo, H.S., Liu, G. et al. A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: Safety, pharmacokinetics, and dceMRI. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-Nov 21, Boston) 2003, Abst C253.
33. Rugo, H.S., Herbst, R.S., Liu, G. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 2005, 23(24): 5474-83.
34. Liu, G., Rugo, H.S., Wilding, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 2005, 23(24): 5464-73.
35. A phase 1 study of AG-013736 (axitinib) in patients with advanced solid tumors (NCT00447005). ClinicalTrials.gov Web site, May 20, 2007.
36. Investigational agent AG-013736 in combinations with standard of care treatments for patient's with advanced solid tumor (NCT00454649). ClinicalTrials.gov Web site, May 20, 2007.
37. Anti-angiogenesis agent AG-013736 in patients with metastatic renal cell carcinoma (NCT00076011). ClinicalTrials.gov Web site, May 20, 2007.
38. Rini, B.I., Rixe, O., Bukowski, R. et al. AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 4509.
39. Rixe, O., Meric, J., Bloch, J. et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3003.
40. George, D.J. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res 2007, 13(2, Pt. 2): 753s-7s.
41. Rugo, H.S., Stopeck, A., Badorf, A., Pithavala, Y., Steinfeldt, H. A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in combination with docetaxel in patients (pts) with metastatic breast cancer (MBC). 28th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2005, Abst 1067.
42. AG-013736 in combination with docetaxel versus docetaxel alone for patients with metastatic breast cancer (NCT00076024). ClinicalTrials.gov Web site, May 20, 2007.
43. Phase 2 study of AG-013736 in patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (NCT00071006). ClinicalTrials.gov Web site, May 20, 2007.
44. Giles, F.J., Bellamy, W.T., Estrov, Z. et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 2006, 30(7): 801-811.
45. Giles, F.J., Steinfeldt, H., Bellamy, W.T. et al. Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Blood 2004, 104(11, Part 1): Abst 1813.
46. Spano, J.P., Moore, M., Kim, S. et al. A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 2-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 13092.
47. AG-013736 in combination with gemcitabine versus gemcitabine alone for patients with metastatic pancreatic cancer (NCT00219557). ClinicalTrials.gov Web site, Mayj 20, 2007.
48. Cohen, E.E., Vokes, E.E., Rosen, L. et al. A phase 2 study of axitinib (AG-013736), a potent inhibitor of VEGFRS, in patients with advanced thyroid cancer. Ann Oncol [31st Eur Soc Med Oncol (ESMO) Congr (Sept 29-Oct 3, Istanbul) 2006] 2006, 17(Suppl. 9): Abst 579PD.
49. Kim, S., Rosen, L., Cohen, E.E. et al. A phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 2-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 5529.
50. Study of the anti-angiogenesis agent AG-013736 in patients with metastatic thyroid cancer (NCT00094055). ClinicalTrials.gov Web site, May 20, 2007.
51. Treatment for patients with metastatic thyroid cancer (NCT00176748). ClinicalTrials.gov Web site, May 20, 2007.
52. Phase 2 study of AG-013736 in patients with doxorubicin-refractory or intolerant thyroid cancer (NCT00389441). ClinicalTrials.gov Web site, May 20, 2007.
53. A phase 2 study in patients with advanced non-small cell lung cancer using new agents with and without docetaxel (NCT00386555). ClinicalTrials.gov Web site, May 20, 2007.
54. Anti-angiogenesis agent AG-013736 in patients with advanced non-small cell lung cancer (NCT00094094). ClinicalTrials.gov Web site, May 20, 2007.
55. Phase 2 study of AG-013736 in patients with refractory metastatic renal cell cancer (NCT00282048). ClinicalTrials.gov Web site, May 20, 2007.
56. Phase 2 study with AG-013736 combined with chemotherapy and bevacizumab in patients with metastatic colorectal cancer (NCT00460603). ClinicalTrials.gov Web site, May 20, 2007.
57. Anti-angiogenesis agent AG-013736 in patients with metastatic melanoma (NCT00094107). ClinicalTrials.gov Web site, May 20, 2007.